Orexo to participate in Pareto Securities´ 15th Annual Healthcare Conference 2024

Rhea-AI Summary

Orexo AB (STO: ORX) (OTCQX: ORXOY) has announced its participation in Pareto Securities' 15th Annual Healthcare Conference on September 19, 2024, at Downtown Camper by Scandic in Stockholm, Sweden. The company's SVP and Head of R&D, Robert Rönn, will deliver a company presentation from 2:25-2:45 CET in the Event Small room.

Additionally, Robert Rönn and Lena Wange, Investor Relations, will be available for one-on-one meetings during the conference. This event provides an opportunity for Orexo to showcase its developments and engage with investors and industry professionals in the healthcare sector.

UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15^th Annual Healthcare Conference, that takes place on September 19, at Downtown Camper by Scandic, Brunkebergstorg 9, Stockholm, Sweden.

On the day, between 2:25-2:45 CET (room Event Small), Robert Rönn, SVP and Head of R&D, will give a company presentation. Robert Rönn and Lena Wange, Investor Relations, will also be available for 1-1 meetings.

For more information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Director
+46 18 780 88 00
ir@orexo.com

About Orexo

Orexo is a Swedish pharmaceutical company with nearly 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2022 amounted to SEK 624 million, and the number of employees to 126. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

About AmorphOX^®

Orexo's world-class drug delivery technology, AmorphOX, is a powder made up of particles which are built using a unique combination of a drug, carrier materials and, optionally, other ingredients. The particles are presented as an amorphous composite of the various ingredients providing for excellent chemical and physical stability, as well as rapid dissolution. The technology works for a broad scope of active ingredients and has been validated in several human clinical studies showing rapid and extensive drug exposure.

For more information about the company please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube. 

The information was submitted for publication at 9 am CET on September 3, 2024. 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-to-participate-in-pareto-securities--15th-annual-healthcare-conference-2024,c4032221

The following files are available for download:

https://news.cision.com/orexo/i/4032221-0-png,c3329843	4032221_0.png
https://news.cision.com/orexo/i/4032221-1-png,c3329844	4032221_1.png

 

View original content:https://www.prnewswire.com/news-releases/orexo-to-participate-in-pareto-securities-15th-annual-healthcare-conference-2024-302236482.html

SOURCE Orexo

FAQ

When and where is Orexo (ORXOY) presenting at the Pareto Securities Healthcare Conference?

Orexo (ORXOY) is presenting on September 19, 2024, from 2:25-2:45 CET in the Event Small room at Downtown Camper by Scandic, Stockholm, Sweden.

Who will be representing Orexo (ORXOY) at the Pareto Securities Healthcare Conference?

Robert Rönn, SVP and Head of R&D, will give the company presentation. Robert Rönn and Lena Wange, Investor Relations, will be available for one-on-one meetings.

What is the significance of Orexo's (ORXOY) participation in the Pareto Securities Healthcare Conference?

Orexo's participation provides an opportunity to showcase its developments, engage with investors, and network with industry professionals in the healthcare sector.

How can investors contact Orexo (ORXOY) for more information about their conference participation?

Investors can contact Lena Wange, IR & Communications Director, at +46 18 780 88 00 or email ir@orexo.com for more information.